11 results
10-K
2020 FY
TSHA
Taysha Gene Therapies Inc
3 Mar 21
Annual report
9:00am
suspension HEK293 cell culture that is highly scalable from the preclinical stages of development through commercialization. We believe this combination … of AAV9, intrathecal delivery and suspension cell culture will accelerate our product development timelines while enhancing our probability
424B4
926xqvmulh3q
25 Sep 20
Prospectus supplement with pricing info
12:00am
S-1/A
0psp5 ots
8 Sep 20
IPO registration (amended)
4:43pm
S-1
46o5u3l
2 Sep 20
IPO registration
5:02pm
DRS
337 lf877ji
3 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next